Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of June 2025, with a specific reporting date of June 23, 2025. The document serves as a transaction notification disclosing share purchases by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with the company.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, or debt metrics. It exclusively reports on specific equity transactions executed on June 20, 2025:
- Ordinary Shares (London Stock Exchange): Purchased at £14.3550 per share.
- American Depositary Shares (NYSE): Purchased at $37.8958 per ADS.
Material Changes and Transaction Details
The filing details nine distinct purchase transactions by directors and associated persons. All transactions were executed on the same date (June 20, 2025) at the same respective prices.
| Name | Position | Instrument | Volume | Price | Exchange |
|---|---|---|---|---|---|
| Lady Susan Symonds | PCA of Non-Executive Chair | Ordinary Shares | 1,350 | £14.3550 | XLON |
| Wendy Becker | Independent Non-Executive Director | Ordinary Shares | 545 | £14.3550 | XLON |
| Elizabeth (Liz) McKee Anderson | Independent Non-Executive Director | ADSs | 258 | $37.8958 | XNYS |
| Charles Bancroft | Senior Independent Non-Executive Director | ADSs | 2,021 | $37.8958 | XNYS |
| Dr Hal Barron | Non-Executive Director | ADSs | 258 | $37.8958 | XNYS |
| Dr Anne Beal | Independent Non-Executive Director | ADSs | 257 | $37.8958 | XNYS |
| Dr Hal Dietz | Independent Non-Executive Director | ADSs | 257 | $37.8958 | XNYS |
| Dr Jeannie Lee | Independent Non-Executive Director | ADSs | 258 | $37.8958 | XNYS |
| Dr Vishal Sikka | Independent Non-Executive Director | ADSs | 889 | $37.8958 | XNYS |
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, or contingencies. It is a regulatory disclosure of insider trading activity only.
Investor Verification Checklist
- Verify the total aggregate value of shares purchased by the board to assess insider confidence levels.
- Confirm the exchange rates between GBP and USD on June 20, 2025, to compare the relative value of purchases on XLON versus XNYS.
- Check subsequent filings to determine if these purchases were part of a pre-arranged trading plan or discretionary buys.
- Review the company's latest Form 20-F for context on overall share buyback programs or dividend policies that may influence these transactions.